PMID- 18021480
OWN - NLM
STAT- MEDLINE
DCOM- 20071227
LR  - 20071120
IS  - 1526-8209 (Print)
IS  - 1526-8209 (Linking)
VI  - 7
IP  - 10
DP  - 2007 Oct
TI  - Comparison of HER2 detection methods between central and regional laboratories in 
      Greece.
PG  - 784-90
AB  - PURPOSE: HER2 gene amplification and overexpression is associated with aggressive 
      breast cancer and poor prognosis. Accurate HER2 testing of patients with breast 
      cancer before treatment is important to ensure that as many patients with 
      HER2-positive breast cancer as possible receive the most appropriate treatment 
      and that women with HER2-negative disease avoid a potentially toxic therapy. This 
      study compares immunohistochemistry (IHC) and fluorescence in situ hybridization 
      (FISH) HER2 testing at central and regional laboratories in Greece. PATIENTS AND 
      METHODS: The HER2 status of 458 breast cancer samples was determined by IHC in 
      central and regional laboratories using commercially available anti-HER2 
      antibodies. FISH analysis, scored as number of signals or a ratio, was 
      subsequently performed by the central laboratory on most samples. Various 
      statistical analyses were used to examine concordance between test center 
      results. RESULTS: Immunohistochemistry HER2 testing was successfully performed on 
      445 samples in the central laboratory and 381 samples in regional laboratories, 
      with good concordance between central and regional laboratories. After FISH 
      analyses of a large proportion of these samples, good correlation was observed 
      between FISH HER2 status and IHC results from the central laboratory but not from 
      regional laboratories. These data suggest that HER2 status determined by IHC in a 
      central laboratory is generally more accurate than that determined by a regional 
      laboratory. CONCLUSION: This study emphasizes the importance of accurate HER2 
      testing and the need to continually check the reproducibility and reliability of 
      the test.
FAU - Papadopoulos, Savvas
AU  - Papadopoulos S
AD  - Department of Pathology, Hygeia Hospital-Harvard Medical International, Maroussi, 
      Athens, Greece. savvas.papadopoulos@hygeia.gr
FAU - Kouvatseas, George
AU  - Kouvatseas G
FAU - Skarlos, Dimosthenis
AU  - Skarlos D
FAU - Malamos, Nikolaos
AU  - Malamos N
FAU - Delliou, Eleftheria
AU  - Delliou E
FAU - Saratsiotou, Ioanna
AU  - Saratsiotou I
FAU - Ardavanis, Alexandros
AU  - Ardavanis A
FAU - Mavroudis, Dimitrios
AU  - Mavroudis D
FAU - Skarpidi, Evangelia
AU  - Skarpidi E
FAU - Arapantoni, Petroula
AU  - Arapantoni P
FAU - Karyda, Irini
AU  - Karyda I
FAU - Patakioyta, Frideriki
AU  - Patakioyta F
FAU - Aravantinos, Gerasimos
AU  - Aravantinos G
FAU - Razis, Evangelia
AU  - Razis E
FAU - Fountzilas, George
AU  - Fountzilas G
FAU - Kosmidis, Paris
AU  - Kosmidis P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Gene Amplification
MH  - *Genes, erbB-2
MH  - Greece
MH  - Humans
MH  - Immunohistochemistry/*standards
MH  - In Situ Hybridization, Fluorescence/*standards
MH  - Laboratories/*standards
MH  - Pathology, Clinical/*standards
MH  - Reproducibility of Results
EDAT- 2007/11/21 09:00
MHDA- 2007/12/28 09:00
CRDT- 2007/11/21 09:00
PHST- 2007/11/21 09:00 [pubmed]
PHST- 2007/12/28 09:00 [medline]
PHST- 2007/11/21 09:00 [entrez]
AID - S1526-8209(11)70783-2 [pii]
AID - 10.3816/CBC.2007.n.040 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2007 Oct;7(10):784-90. doi: 10.3816/CBC.2007.n.040.